Pathophysiological features of chronic cerebrovascular diseases and possibilities of complex neuroprotective therapy

The article discusses the principles of neuroprotective therapy as a pathogenetically justified direction in chronic cerebrovascular diseases (CVD). The results of numerous clinical trials demonstrated efficacy, safety, a wide range of pharmacological effects and good tolerability of the powerful antioxidant Idebenone (Neyromet), as well as domestic cytoprotector, Choline alphosceratus of (Cerepro®), affecting the basic pathophysiological processes of the ischemic cascade at CVD. The role of rational multimodal pharmacotherapy of CVD, which provides the necessary energy for the processes of neuroprotection and neuroplasticity of brain cells, is emphasized.

1. Fedin A.I. Diagnosis and treatment of chronic cerebral ischemia. Consilium Medicum. 2016;18(2):8-12. (In Russ).

2. Johnston S.C., Nquyen-Huynh M.N., Schwarz M.E. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2008;60:301-303.

3. Vereshchagin N.V. et al. Brain pathology in atherosclerosis and arterial hypertension. M., 1997. (In Russ).

4. Nikiforov A.S., Konovalov A.N., Gusev E.I. Clinical neurology. M .: Medicine, 2002. (In Russ).

5. Gusev E.I., Skvortsova V.I., Cerebral ischemia. M.: Medicine, 2001. (In Russ).

6. Illarioshkin S.N. Cellular energy dysfunction in nervous system diseases. Nervnye Bolezni. 2012;1:34-38. (In Russ).

7. Gusev E.I., Skvortsova V.I., Platonova I.A. Treatment of ischemic stroke. Consilium Medicum (Spetsvypusk Nevrologiya). 2003:18-25. (In Russ).

8. Ivanov G.E. Medical rehabilitation in Russia. Development prospects. Consilium Medicum. 2016;13: 9-13. (In Russ).

9. Kamchatnov P.R., Mikhailova N.A., Zhdanova S.V. Correction of free-radical oxidation in patients with cerebral circulation disorders. Trudny Patsient. 2010;8(6–7):26–33. (In Russ).

10. Montenegro L., Turnaturi R., Parenti C., Pasquinucci L. Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy. Nanomaterials (Basel). 2018 Feb 5;8(2). pii: E87. doi: 10.3390/nano8020087.

11. Rachin A.P., Averchenkova A.A. Idebenon (Noben): from theory to practice. Zhurnal Nevrologii i Psikhiatrii. 2011;5:81-84. (In Russ).

12. Meier T., Buyse G. Idebenone: An emerging therapy for Friedreich ataxia. J. Neurol. 2009;256:25–30.

13. El-Hattab A.W., Zarante A.M., Almannai M., Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol. Genet. Metab. 2017;122:1–9.

14. Erb M., Hoffmann-Enger B., Deppe H., Soeberdt M., Haefeli R.H., Rummey C., Feurer A., Gueven N. Features of idebenone and related shortchain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS ONE. 2012;7:e36153.

15. Civenni G., Bezzi P., Trotti D., et al. Inhibitory effect of the neuroprotective agent idebenone and arachidonic acid metabolism in astrocytes. Eur J Pharmacol. 1999;370:161-167.

16. Cardoso S.M., Pereira C., Oliveira C.R. The protective effect of vitamin E, idebenone and reduced glutathione on free radical mediated injury in rat brain synaptosomes. Biochem Biophys Res Commun. 1998;246:703-710.

17. Jaber S., Polster B.M. Idebenone and Neuroprotection: Antioxidant, Pro-oxidant, or Electron Carrier? J. Bioenerg. Biomembr. 2015;47:111–118.

18. Kakihana M., Yamazaki N., Nagaoka A. Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia. Arch Gerontol Geriatr. 1989;8:247-256.

19. Kakihana M., Yamazaki N., Nagaoka A. Effects of idebenone (CV-2619) on the concentrations of acetylcholine and choline in various brain regions of rats with cerebral ischemia. Jpn J Pharmacol. 1984;36:357-363.

20. Fiebiger S.M., Bros H., Grobosch T., Janssen A., Chanvillard C., Paul F., Dörr J., Millward J., Infante-Duarte C. The antioxidant idebenone fails to prevent or attenuate chronic experimental auto-immune encephalomyelitis in the mouse. J. Neuroimmunol. 2013;262:66–71.

21. Nabeshima T., Nitta A., Fuji K., et al. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrainlesioned rats. Gerontology. 1994;40:S46S56.

22. Nitta A., Hasegawa T., Nabeshima T. Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain. Neurosci Lett. 1993;163:219-222.

23. Yamada K., Tanaka T., Han D., et al. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(142)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci. 1999;11:83-90.

24. Fadda L.M., Hagar H., Mohamed A.M., Ali H.M. Quercetin and Idebenone Ameliorate Oxidative Stress, Inflammation, DNA damage, and Apoptosis Induced by Titanium Dioxide Nanoparticles in Rat Liver. Dose Response. 2018 Dec 9;16(4):1559325818812188.

25. Lauro F., Ilari S., Giancotti L.A., Ventura C.A., Morabito C., Gliozzi M., Malafoglia V., Palma E., Paolino D., Mollace V., Muscoli C. Pharmacological effect of a new idebenone formulation in a model of carrageenan-induced inflammatory pain. Pharmacol Res. 2016 Sep;111:767-773. doi: 10.1016/j.phrs.2016.07.043.

26. Tomilov A., Allen S., Hui C.K., Bettaieb A., Cortopassi G. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res. 2018 Nov;137:89-103. doi: 10.1016/j.phrs.2018.09.024.

27. Zhang Z.W., Xu X.C., Liu T., Yuan S. Mitochondrion-permeable antioxidants to treat ROS-burst-mediated acute diseases. Oxidative Med. Cell. Longev. 2016;2016:6859523.

28. Parkinson M.H., Schulz J.B., Giunti P. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J. Neurochem. 2013;1:125–141.

29. Strawser C., Schadt K., Hauser L., McCormick A., Wells M., Larkindale J., Lin H., Lynch D.R. Pharmacological therapeutics in Friedreich ataxia: The present state. Expert Rev. Neurother. 2017;17:895–907.

30. Strawser C.J., Schadt K.A., Lynch D.R. Therapeutic approaches for the treatment of Friedreich’s ataxia. Expert Rev. Neurother. 2014;14:949–957.

31. El-Hattab A.W., Zarante A.M., Almannai M., Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol. Genet. Metab. 2017;122:1–9.

32. Kumar A., Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Front. Pharmacol. 2015;6:206.

33. Gutzmann H., Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: Update on a 2-year double-blind multicentre study. In Alzheimer’s Disease – From Basic Research to Clinical Applications; Springer: Vienna, Austria, 1998; 54:301–310.

34. Thal L.J., Grundman M., Berg J., Ernstrom K., Margolin R., Pfeiffer E., Weiner M.F., Zamrini E., Thomas R.G. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology. 2003;61:1498–1502.

35. Gutzmann H., Kuhl K.P., Hadler D. et al. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: Results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry. 2002;35:12-18.

36. Hashimoto K. Idebenone. In: Evidence-based dementia practice. Eds. N. Qizilbash et al. Oxford: Blackwell Sciences. 2002:530-535.

37. Damulin I.V. Use of idebenone (noben) in neurological practice. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006; 11: 66-71. (In Russ).

38. Lin P., Liu J., Ren M., Ji K., Li L., Zhang B., Gong Y., Yan C. Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3β/β-catenin signalling pathways. Biochem. Biophys. Res. Commun. 2015;465:548–555.

39. Nakano T., Miyasaka M., Mori K., et al. Effects of idebenone on electroencephalograms of patients with cerebrovascular disorders. Arch Gerontol Geriatr. 1989;8:355-366.

40. Gutzmann H., Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm. 1998;54:S301-S310.

41. Weyer G., Babej-Dolle R.M., Hadler D. et al. A controlled study of two doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology. 1997;36:73-82.

42. Bergamasco B., Scarzella L., La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol. 1994;9:161-168.

43. Batysheva T.T., Zaitsev K.A., Kamchatnov P.R., Boyko A.N., et al. Efficacy of choline alfoscerate (gliatilin) in patients mild cognitive impairment of vascular genesis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. V Pomosch Prakticheskomu Vrachu. 2011;9/2:41-45. (In Russ).

44. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269.

45. Traini E., Bramanti V ., Amenta F . Choline alphoscerate (alpha-glycerylphosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr. Alzheimer Res. 2013;10(10):1070–1079.

46. Tayebati S., Di Tullio M., Tomassoni D., Amenta F. Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J Neurol Sci. 2009;15;283(1-2):187-194.

47. Ceda G. GH responses to GHRH in old subjects and in patients with senile dementia of the Alzheimer’s type: the effects of an acetylcholine precursor. Advances in the Biosciences. 1993;87:425-428.

48. Parnetti L., Amenta F., Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041-2055.

49. Parnetti L., Abate G., Bartorelli L. et al. Multicentre study of l-alphaglyceryl-phosphorylcholine vs. ST200 among patients with probable senile dementia of Alzheimer’s type. Drugs Aging. 1993;3:159–164.

50. Batysheva T.T., Nesterova O.S., Otcheskaya O.V., et al. Use of Cereton in patients with mild cognitive impairment of vascular origin. Trudny Patsient. 2009;4-5:10-2. (In Russ).

51. Shavlovskaya O.A. Experience of using Cereton® (choline alphoscerat) in clinical practice. RMJ. 2011;9:557. (In Russ).